Drug Profile
Research programme: antimalarials - Pfizer/Medicines for Malaria Venture
Alternative Names: AN-3661Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals; Medicines for Malaria Venture
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in USA
- 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
- 18 Mar 2011 Preclinical trials in Malaria in USA (unspecified route)